STOCKHOLM--(BUSINESS WIRE)--Cantargia AB (“Cantargia”) has received approval in Japan and Mexico for its patent application covering IL1RAP as a target molecule for antibody therapy and leukemia diagnostics.
The protection covers treatment and diagnostics of leukemic cancer diseases, and the approval means that Cantargia’s patent will be protected in Japan and Mexico until 2030. Cantargia’s application is now protected in Europe, Japan, South Africa, Mexico and Australia. The corresponding patent applications are being examined by the relevant agencies in the US, China and other countries. Cantargia also has two further patent families related to its CAN04 product candidate.
“Japan is one of the largest markets for pharmaceuticals and this patent approval is of great importance for Cantargia as well as for commercialization of our product candidate CAN04. Mexico is a territory which in addition to its size has a potential of strategic importance for commercialization in neighboring markets. We have thus taken a further step to strengthen the protection around our product candidate CAN04", CEO Göran Forsberg says.
This information was brought to you by Cision http://news.cision.com